Trial | NCT00190580  Report issue

Title

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    valsartan ...

  • Study Participants

    312
The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added to conventional antihypertensive therapy.
It is widely recognized that suppression of the renin-angiotensin system ameliorates progression of chronic kidney disease (CKD) and that CKD is an important risk factor for development of cardiovascular disease. However, it has not been fully clarified if amelioration of CKD leads to the lower incidence of cardiovascular disease. The purpose of this study is to determine whether the angiotensin II receptor antagonist valsartan, in combination with conventional antihypertensive therapy, will ameliorate progression of both CKD and cardiovascular disease. The primary outcome is courses of renal and cardiac function. The secondary outcome is a composite of a doubling of serum creatinine concentration, end-stage renal disease, myocardial infarction, coronary revascularization, stroke, hospitalization for unstable angina, hospitalization for heart failure or death from cardiovascular causes.
Study Started
Feb 28
2003
Primary Completion
Apr 30
2008
Study Completion
Apr 30
2008
Last Update
Mar 31
2015
Estimate

Drug valsartan

valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs

  • Other names: Diovan 40mg or Diovan 80mg

Drug Conventional antihypertensive drugs

Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers

  • Other names: any antihypertensive drug except ARB

1 Experimental

2 Experimental

Criteria 

Inclusion Criteria:

CKD with serum creatinine more than 2.0 mg/dl
Blood pressure more than 130/85 mmHg
20 years old or above

Exclusion Criteria:

End-stage renal disease with maintenance dialysis
Polycystic kidney disease
Collagen disease
Malignant or accelerated hypertension
No Results Posted